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Genetic studies of intellectual disability and identification of monogenic causes of obesity in humans have made immense contribution
toward the understanding of the brain and control of bodymass. The leptin>melanocortin> SIM1 pathway is dysregulated inmultiple
monogenic human obesity syndromes but its downstream targets are still unknown. In ten individuals from six families, with overlap-
ping 6q16.1 deletions, we describe a disorder of variable developmental delay, intellectual disability, and susceptibility to obesity and
hyperphagia. The 6q16.1 deletions segregated with the phenotype in multiplex families and were shown to be de novo in four families,
and there was dramatic phenotypic overlap among affected individuals who were independently ascertained without bias from clinical
features. Analysis of the deletions revealed a ~350 kb critical region on chromosome 6q16.1 that encompasses a gene for proneuronal
transcription factor POU3F2, which is important for hypothalamic development and function. Using morpholino andmutant zebrafish
models, we show that POU3F2 lies downstream of SIM1 and controls oxytocin expression in the hypothalamic neuroendocrine preoptic
area. We show that this finding is consistent with the expression patterns of POU3F2 and related genes in the human brain. Our work
helps to further delineate the neuro-endocrine control of energy balance/body mass and demonstrates that this molecular pathway is
conserved across multiple species.Intellectual disability has an estimated prevalence of 1.5%–
2.0%1 and is a genetically and phenotypically heteroge-
neous group of disorders. Studies of genetic causes of
intellectual disability have made immense contributions
toward our understanding of the human brain. Obesity
and related co-morbidities are a major public health
concern across the world.2 Understanding the control
mechanisms of body mass is a fundamental question for
biology and an important area for research.
Rare copy-number variations (CNVs) are linked with
a range of phenotypes and are a particularly well-recog-
nized cause of developmental disorders and intellectual
disability.3,4 Additionally, rare CNVs can provide insights
into the single-gene causes of human disorders5,6 and
can provide clues toward the genetic basis and molecular
mechanisms of commoner complex conditions and
traits7,8 including obesity.9–14 Here, we describe a study
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susceptibility to obesity and hyperphagia along with
extended analyses that define the likely critical gene for
the phenotype and its role in neuro-endocrine control of
energy balance and body mass.
Ethics approval for the study was obtained from the NHS
ethics committee (11/H1003/3) and the University of
Manchester. Informed consent was taken from all partici-
pants recruited into the study from the Manchester Centre
for Genomic Medicine. Other participants provided con-
sent to publish their data to the recruiting clinician.
We identified a family (referred to as family 1) with four
members, most of whom were affected with neonatal hy-
potonia, gross motor delay, speech delay, intellectual
disability, behavioral problems, obesity, and hyperphagia
with onset from mid-childhood (Figure 1A). Their clinical
features are summarized in Table 1. Family history sug-
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Figure 1. Results of Clinical Genetic Studies
(A) Pedigrees of families. Array comparative genomic hybridization (aCGH) on a DNA sample from individual II-4 of family 1 revealed a
1–1.2 Mb heterozygous deletion on chromosome 6q16.1q16.2 that segregated with the phenotype in the family. We interrogated the
local clinical cytogenetics databases of our collaborators for<2 Mb 6q16 deletions that do not include SIM1 and identified six additional
individuals from five families (family 2–6). In four individuals, deletions were proven to have arisen de novo. One individual in family 3
had inherited the deletion from her affected mother. Standard symbols have been used to draw the pedigrees. Dark squares represent
affected individuals who were found to have 6q16 deletion. Squares or circles with ‘‘N’’ denote individuals who were tested and found
not to have the familial 6q16 deletion. ‘‘?’’ denote individuals whose genotype information is not available.
(B) Results of copy-number analysis. The top panel represents the chromosome bands with the copy-number state of the corresponding
hybridized probes from the aCGH results of individual II-4 of family 1. The middle panel focuses on the 6q16 region. The horizontal red
bars in the bottom panel show the minimum extent of the microdeletions (in hg19 build) in all five families. The bottom panel is
annotated with respective gene loci. The yellow box circumscribes the maximum common overlapping region of the deletion in the
five families.
(C) Metaphase fluorescent in situ hybridization (FISH) from individual II-4 from family 1. FISH was undertaken with spectrum green
fluorophore-prelabeled RP11-290C18 BAC probe (The Centre for Applied Genomics, Toronto, Canada) whichmaps to the 6q16.2 region
(chr6: 99,813,064–99,990,209). A spectrum orange fluorophore-prelabeled 6q subtelomeric probe (Abbott Molecular) was used as a
control. The FISH independently confirmed the heterozygous 6q16.2 deletion in this individual.Prader Willi syndrome (PW syndrome or PWS) (MIM:
176270) was ruled out via methylation-specific multiplex
ligand probe amplification. An array comparative genomic
hybridization (aCGH) was performed on a DNA sample
from individual II-4 via CytoSure ISCAv2 (8x60k) microar-
ray (Oxford Gene Technology) according to the manufac-
turer’s protocol. CytoSure Interpret v3.4.3 software was
used for data analysis, and copy-number aberrations were
detected using a minimum of four markers per segment
with abnormal log2 ratios (~180 kb backbone and ~15 kb
targeted resolution). This revealed a 1–1.2 Mb deletion on
chromosome 6q16.1q16.2 (chr6: 99,218,535–100,260,996
in hg19) (DECIPHER: 265018) (Figure 1B). The deletion
was absent in the Database of Genomic Variants (DGV)
and in more than 6,000 local controls. Metaphase fluores-364 The American Journal of Human Genetics 98, 363–372, Februarycent in situ hybridization (FISH) analysis performed on
lymphocyte cell suspensions using standard protocols
independently confirmed the 6q16 deletion in II-4
(Figure 1C) and in all affected family members (II-3, II-6,
and I-1). The deletion was absent in all the unaffected sib-
lings. We could not investigate the origin of the deletion in
this family because samples from parents of I-1 were not
available for testing.
PWS is a classic contiguous gene syndrome that in the
majority of affected individuals results from deletion of
paternal copies of the imprinted chromosome 15q11–
q13 locus.15 ‘‘PW-like syndrome associated with chromo-
some 6’’ is another recognized clinical entity (MIM:
176270) that has been described with different genomic
deletions of chromosome 6. Of these, some individuals4, 2016
with interstitial 6q16 deletions most closely resemble the
phenotype of PWS. Most such 6q16 deletions encompass
SIM1 (single minded homolog 1 [MIM: 603128]).9 SIM1
is part of the central molecular pathway that regulates
body mass. In brief, the adipocyte-derived hormone
leptin (LEP [MIM: 164160]) and its widely expressed
leptin receptor (LEPR [MIM: 601007]) stimulate proopio-
melanocortin (POMC [MIM: 176830]) expression in the
hypothalamus.16 POMC is enzymatically cleaved to form
a- and b-melanocyte-stimulating hormones, which acti-
vate signaling via melanocortin-4 receptor (MC4R [MIM:
155541]) to induce expression of SIM1. This pathway is
dysregulated in multiple monogenic human obesity syn-
dromes (Table S1). Disruptions or heterozygous loss-of-
function mutations of SIM1 cause severe obesity (MIM:
601665).10–12 SIM1 is a master regulator of neurogenesis
and its optimum dosage is essential for the formation of
supraoptic (SON) and paraventricular (PVN) hypothalamic
nuclei that play a central role in body mass regulation.17,18
In mice, Sim1 haploinsufficiency results in neuroanatom-
ical defects but hyperphagic obesity develops even in the
absence of structural abnormalities, which is thought to
be mediated by deficiency of oxytocin.19 However, the
mechanism of how SIM1 regulates oxytocin is not known.
There is no known conserved binding site for Sim1 or its
heterodimer partner Arnt2 in 5 kb upstream or down-
stream genomic sequence of Oxt (oxytocin).19 Interest-
ingly, some individuals with PWS-like phenotype have
6q16 deletions that do not encompass SIM1.9 This suggests
that there is at least one other gene located on 6q16, loss of
which can cause intellectual disability and obesity and
perhaps lies within the leptin > melanocortin > SIM1
pathway.
The deletion in family 1 encompasses nine known pro-
tein-coding genes: POU3F2 (MIM: 600494), FBXL4 (MIM:
605654), FAXC, COQ3 (MIM: 605196), PNISR (MIM:
616653), USP45, TSTD3, CCNC (MIM: 123838), and
PRDM13 (Figure 1B). Notably, the deletion does not
include SIM1. Constitutional genomic rearrangements
can convey phenotypes through a number of mechanisms
including long-range effects.3 For genomic deletions, the
most commonmechanism is haploinsufficiency of a single
dosage-sensitive critical gene or a group of contiguous
genes located within the deleted interval. We, therefore,
first investigated the likely effect of haploinsufficiency of
the genes within the 6q16.1 deletion. Truncating variants
have been described in seven of these nine genes in the
general population (Table S2). Loss of one copy of any of
these single genes, therefore, is less likely to be driving
the congenital or childhood-onset phenotypes in family 1.
Out of the remaining two genes, population variant fre-
quency data was unavailable for TSTD3, and POU3F2 was
the only gene with no known truncating mutations and
low haploinsufficiency index score.20 This made POU3F2
an important candidate for further investigation. Another
potential gene of interest was FAXC because truncating
variants in this gene are extremely rare (Table S2).The AmericWe interrogated the local clinical cytogenetic databases
of our collaborators for <2 Mb 6q16 deletions that
excluded SIM1 and identified six additional individuals
from five families (Figure 1; Table S3). Their clinical fea-
tures were remarkably similar (Table 1). In four individuals,
deletions were proven to be de novo in origin and one in-
dividual had inherited the deletion from her similarly
affected mother (Figure 1).
Overall, in ten individuals (six males and four females)
from six families, we report identification of a disorder of
developmental delay and intellectual disability with sus-
ceptibility to obesity caused by heterozygous 6q16 dele-
tions that encompass POU3F2 but do not include SIM1
(Figure 1; Table 1). Our findings are supported by (1) de
novo origin of the deletions in at least one affected mem-
ber of four families; (2) segregation of the phenotype
with the deletion inmultiplex families; and (3) phenotypic
similarity among affected individuals who were indepen-
dently ascertained without any bias from clinical features.
Birth weights of most individuals were within the normal
range. Most individuals presented with neonatal hypoto-
nia, although it was not as severe as what is generally
encountered in PWS. Unlike PWS, neonatal feeding diffi-
culty, although encountered, was not a major feature in
this group of individuals. Most individuals had mild gross
and finemotor delay but one individual had normal motor
development and another was severely delayed. Most indi-
viduals achieved independent sitting between the ages of 6
and 12 months and independent walking between 14 and
21 months. Most individuals had intellectual disability
that ranged frommild to moderate. One individual had se-
vere intellectual disability. The body mass index (BMI)
could be calculated for four adults in our cohort and it
ranged between 3.62 and 4.59 SDs above the mean, putt-
ing them in either severely or very severely obese cate-
gories. The BMI of all but one child was on or above the
99th centile (range: þ1.51 to þ4.27 SDs) in the obese cate-
gory. The BMI of one 13-year-old girl was on the 91st cen-
tile, putting her in the overweight category. The age of
onset of obesity ranged from the first year of life to mid-
teens. All but one affected individual was reported to
have abnormally increased appetite. Interestingly, in all
the cases where information was available, the onset of
obesity preceded hyperphagia. The excess weight in all in-
dividuals was more predominant in the truncal area. Rela-
tives frequently described problems with unpredictable
behavior with unprovoked outbursts of aggression, tan-
trums, impulsivity, mood swings, and emotional lability.
Some individuals were described as withdrawn and poor
at social interaction. Interestingly, a recent genome-wide
association study revealed 6q16.1 as a risk locus for bipolar
disorder.21
A combined analysis of all the deletions revealed that the
maximum critical region for the phenotype included only
two genes, POU3F2 and FBXL4 (Figure 1B). Loss-of-func-
tion and truncating FBXL4 mutations cause autosomal-
recessive encephalomyopathic type mitochondrial DNAan Journal of Human Genetics 98, 363–372, February 4, 2016 365
Table 1. Clinical Features of Individuals in This Study
Individual#
Pedigree
Identifiera Inheritance Sex Age
Birth weight
in kg (centile)
Neonatal
Hypotonia
Feeding
Difficulties
in Infancy
Motor
Delay
Speech
Delay
Learning
Disability
1 1-I-1 NA male 61 NA yes NA yes yes moderate
2 1-II-3 paternal male 21 4.8 (98th) yes no mild yes mild
3 1-II-4 paternal male 19 4.3 (91st) yes no mild yes moderate
4 1-II-6 paternal male 10 3.5 (50th) no no mild yes moderate
5 2-II-1 DN female 13 3.4 (50th) no no no yes moderate
6 3-II-2 DN female 52 3.25 (50th) yes no mild moderate mild
7 3-III-1 maternal female 26 3.1 (25th) yes no mild mild mild
8 4-II-1 DN male 9 3.69 (83rd) yes no mild mild mild
9 5-II-1 DN female 4 3.3 (75th) yes yes severe severe severe
10 6-II-1 NA male 16 3.5 (50th) yes yes moderate severe moderate
Abbreviations are as follows: DN, de novo; NA, not available; IQ, intelligence quotient; WISC, Wechsler Intelligence Scale for Children.
aPedigree identifier: Family#-Generation#-individual# (compare with Figure 1).
bBMI categories for adults are 25 to 30, overweight; 30 to 35, moderately obese; 35 to 40, severely obese; over 40, very severely obese.
cBMI categories for children are 85th to 95th centile, overweight; above 95th centile, obese.depletion syndrome (MIM: 615471) in which heterozy-
gous carriers are phenotypically unaffected.22 Thus
POU3F2 remained as the most likely critical gene for the
phenotype of 6q16.1 deletions.
Class III POU genes, POU3F1 (MIM: 602479), POU3F2,
POU3F3 (MIM: 602480), and POU3F4 (MIM: 300039),
belong to a family of transcription factors that bind to
the octameric DNA sequence 50-ATGCAAAT-30. These
genes share a highly homologous POU domain and are
predominantly expressed in the central nervous system.
Pou3f2 and Pou3f3 upregulate proneuronal genes23,24 and
are required for production, migration, and positioning
of neocortical neurons.25,26 In vivo, Pou3f2 shares func-
tional redundancy with Pou3f3 and simultaneous disrup-366 The American Journal of Human Genetics 98, 363–372, Februarytion of both genes is required to disturb normal formation
of the neocortex and migration of neurons.26 However,
Pou3f3 single mutants exhibit an abnormal hippocam-
pus26 and Pou3f2 single mutants display abnormal neuro-
secretory neurons of the hippocampal PVN and SON27,28
thus demonstrating their essential roles in the develop-
ment of specific areas of the brain.
We examined data from the Human Brain Transcrip-
tome Project29 that confirmed that POU3F2 is expressed
throughout fetal and adult life in the human brain
(Figure S1). We then examined data in the Allen Human
Brain Atlas30 via the Brain Explorer tool for expression
patterning of POU3F2 and related genes in the adult hypo-
thalamus and hippocampus (Figure S2). This confirmed4, 2016
Behavioral Issues
Latest Weight
in kg (centile)
Latest Height
in cm
(centile)
Latest BMI
(SD)
BMI
Category
Obesity
Onset
(years) Hyperphagia
Hyperphagia
Onset (years) Other Comments
mood swings,
occasional
aggressiveness
NA 172 (25th) NA NA NA yes NA diabetes mellitus at
55 years, angioplasty
at 60 years
mood swings,
acute depression,
occasional
aggressiveness
117.8 (>99th) 177.3 (50th) 37.5 (3.77) severely
obeseb
15 yes 19 right hydrocele,
undescended testis,
and inguinal hernia;
left convergent squint
withdrawn,
occasional
aggressiveness
140.0 (>99th) 172 (25th) 47.3 (4.59) very severely
obeseb
10 yes 12 left convergent squint
tantrums,
emotional
liability
59.5 (> 99th) 139 (50th–
75th)
30.8 (4.27) obesec 1 yes 8 left undescended testis,
right hydrocele; right
talipes; convergent
squint
poor social
interaction,
occasional
aggressiveness
57 (75 90th) 160 (75th) 22.3 (1.51) overweightc NA no NA partial regression of
speech after 2 years;
at 13 years: WISC-III
total IQ ¼ 48, verbal
IQ ¼ 45; performance
IQ ¼ 62
tantrums, rigid
behavior
101 (95th) 161 (25th) 38.9 (3.87) severely
obeseb
19 yes 21 clumsiness and poor
articulation; lordosis;
hyperhidrosis.
rigid behavior,
occasional
aggressiveness
95 (NA) 160 (NA) 37.1 (3.62) severely
obeseb
11 yes 14 hypothyroidism;
systemic lupus
erythematous-like
illness
impulsiveness,
occasional
aggressiveness
66 (99th) 152.5 (99th) 28.38 (3.57) obesec 4 yes 8 IQ ¼ 72 (7.5 years)
sleep problems 24.6 (>97th) 109.5 (98th) 20.7 (2.99) obesec 2 yes NA gastro-esophageal
reflux; very poor
expressive speech;
thin corpus callosum;
kyphosis
occasional
aggressiveness
poor social
interaction
88.9 (99th) 184 (91st) 26.3 (2.29) obesec 10 yes NA auditory memory
problems and
dyspraxia; left
cerebellar arachnoid
cystthat POU3F2 and POU3F3 are highly expressed in the
human hypothalamus and hippocampus, respectively
(Figure S2), thus mirroring the known expression pattern
in mice.
We also explored the expression of POU3F2 through
quantitative RT-PCR (qRT-PCR) in transformed lympho-
blastoid cell lines (LCLs) from affected individual II-6 and
his unaffected sibling II-1 in family 1. Amplification of
the POU3F2 transcript occurred at very late cycle numbers,
suggesting that this gene is expressed at very low levels in
peripheral lymphocytes. We observed an approximate
50% reduction in POU3F2 expression in LCLs from the
affected individual in comparison to cells derived from
the unaffected sibling (Figure S3), although the resultsThe Americwere not statistically significant (most likely due to the
low expression levels resulting in high variability) even
after nine technical repeats and by using a high concentra-
tion of cDNA template.
We explored the role of POU3F2 in hypothalamic devel-
opment using zebrafishmodels. We determined that zebra-
fish have two orthologs of human POU3F2, pou3f2a and
pou3f2b (Figures S4 and S5 and Table S4). All procedures
were in accordance with NIH guidelines on the care and
use of animals and were approved by the Georgetown Uni-
versity Institutional Animal Care and Use Committee, Pro-
tocol 11-008. Zebrafish (Danio rerio) were raised, main-
tained, and crossed as described previously.31 Embryos
were raised at 28C and staging was determined byan Journal of Human Genetics 98, 363–372, February 4, 2016 367
Figure 2. Effect of pou3f2a and pou3f2b
Morpholino Oligonucleotides Knockdown
on oxt- and avp-Expressing Cells
Representative ventral views of 48 hpf em-
bryos stained for oxt (A–D) and avp (F–H)
expression by whole mount in situ hybrid-
ization (WISH). The white arrowheads
indicate the location of neuroendocrine
preoptic area (NPO) and black arrows indi-
cate avp expression in the ventral hypo-
thalamus.
(A) Control MO showing full oxt expres-
sion (n ¼ 67).
(B) pou3f2a MO showing reduced oxt
expression (n ¼ 45).
(C) pou3f2b MO showing reduced oxt
expression (n ¼ 69).
(D) pou3f2a/pou3f2b MO-injected embryos
showing highly reduced oxt expression
(n ¼ 96).
(E) Quantification of oxt expression. 82%
of control MO-injected embryos had
full oxt expression (blue). Injection of
either pou3f2a or pou3f2b MO resulted
in majority of the embryos with reduced
oxt expression (green). Simultaneous injec-
tion of pou3f2a and pou3f2b MOs resulted
in highly reduced oxt expression (yellow) majority of the embryos with 26% showing no expression (red).
(F) Control MO showing full avp expression within the NPO and ventral hypothalamus.
(G and H) pou3f2a (G) and pou3f2b (H) MO showing no avp expression within the NPO without any reductions in its expression in the
ventral hypothalamus.both hours post fertilization (hpf) andmorphological char-
acteristics.32
Plasmids for pou3f2a and pou3f2b were obtained from
RZPD (German Science Centre for Genome Research).
The pou3f2a DIG-labeled antisense riboprobe was gener-
ated using T7 polymerase from RsrII linearized plasmid
(DIG-labeling Kit, Roche). For pou3f2b, the cDNA was
subcloned into pBluescript II (Stratagene) and then
linearized with KpnI for riboprobe synthesis using T7.
Single- and double-labeled whole mount in situ hybridiza-
tion (WISH) was performed according to previously
published protocol.33 We determined that, in zebrafish,
by 48 hpf, pou3f2a and pou3f2b are normally expressed
in the diencephalon, the midbrain tegmentum, and
throughout the hindbrain (Figure S6). However, within
the diencephalon, strong expression of pou3f2a and
pou3f2b remains restricted to a small area of the neuro-
endocrine preoptic area (NPO). Double-labeled WISH
demonstrated that in the NPO, pou3f2a and pou3f2b
mRNAs normally co-localize in subsets of oxt-expressing
cells (Figure S7).
Antisense morpholino oligonucleotides (MOs) targeting
pou3f2a or pou3f2b (Table S5) were injected independently
or simultaneously into zebrafish embryos at the 1- to 2-cell
stage in 13 Danieau’s solution at 1.0 ng/embryo. The total
amount of injected MO in each group was kept constant
for each embryo. Oxt and avp probes were generated as pre-
viously described.33–35 Oxt expression in approximately 30
cells was quantified as full expression, in 5–15 cells as
reduced expression, in 1–4 cells as highly reduced
expression, and in 0 cells as no expression. Antisense368 The American Journal of Human Genetics 98, 363–372, FebruaryMO-mediated knockdown of pou3f2a or pou3f2b individu-
ally resulted in significantly decreased oxt expression (Fig-
ure 2). Simultaneous knockdown of pou3f2a and pou3f2b
decreased oxt expression further (Figure 2), demonstrating
the role of POU3F2 in regulating OXT expression. Likewise,
pou3f2a or pou3f2b MOs individually eliminated avp
expression within the NPO. However, neither pou3f2a
nor pou3f2b MOs reduced avp expression in the ventral
hypothalamus, demonstrating the specificity of the MOs.
We have previously shown that MO knockdown of
sim1a eliminates oxt and avp expression in zebrafish
NPO.33,34 Additionally, oxytocin expression is decreased
in Sim1 haploinsufficient mice19 and there is evidence
that Sim1 might regulate Pou3f2 expression in mice.17
MO injections for sim1 were performed as previously pub-
lished33,36 and WISH staining for pou3f2a/b expression in
the NPO was quantified using an ordinal scale from 0 to 2
as follows: 0, no staining; 1, uncertain or dramatically
reduced staining; 2, obvious (normal) staining. This
showed significant reduction of pou3f2a and pou3f2b
expression levels in sim1 morphants (Figures 3A–3D and
3I). ARNT2 encodes a dimerization partner of SIM1 for
the development of the hypothalamus.37 In the NPO of
previously described38 homozygous arnt2hi2639Tg null
zebrafish mutant embryos (Table S6), the expression of
pou3f2a and pou3f2b was undetectable (Figures 3E–3H
and 3J), demonstrating the role of SIM1-ARNT2 dimers in
regulating POU3F2 expression in the hypothalamus. We
also examined the expression of sim1a in NPO of pou3f2a
and pou3f2bmorphants and found no obvious differences
from controls (Figure S7).4, 2016
Figure 3. pou3f2a and pou3f2b Expression Is Reduced in sim1a Morphants and Is Eliminated in arnt2-Null Mutant Embryos
Representative lateral views of embryos stained for pou3f2a or pou3f2b expression by WISH at 48 hpf. Eyes have been removed to better
visualize the staining in the NPO (indicated by white arrowheads and magnified views are shown in the insets).
(A and C) Control morpholino oligonucleotide (MO)-injected embryos showing normal expression of pou3f2a (n ¼ 11) (A) and pou3f2b
(n ¼ 10) (C).
(B and D) sim1a MO knockdown reduces the level of pou3f2a (n ¼ 9) (B) and pou3f2b (n ¼ 12) (D) expression.
(E and G) Wild-type embryos showing strong pou3f2a (n ¼ 7) (E) and pou3f2b (n ¼ 13) (G) staining in the NPO.
(F and H) arnt2-null mutant embryos showing an absence of pou3f2a (nwt¼ 7; nhet¼ 12; nhom¼ 8) (F) and pou3f2b (nwt¼ 13; nhet n¼ 28;
nhom ¼ 18) (H) in the NPO.
(I and J) Both sim1 MO-injected embryos (I) and arnt2-null mutants (J) resulted in a significant number of embryos showing reduced
(orange) or no (red) expression of pou3f2a and pou3f2b indicating that their expression in the NPO is dependent on functional
sim1a-arnt2 heterodimers.Overall, the zebrafish experiments showed that POU3F2
is a downstream target for the SIM1-ARNT2 dimer in the
leptin > melanocortin > SIM1 pathway and that POU3F2
plays an important role in regulating expression of OXT
in the hypothalamus.
The maximum critical region for the 6q16.1 deletions
and our zebrafish work suggests that the phenotype of
the individuals described here is due to haploinsufficiency
of POU3F2. Mice that are homozygous for loss-of-function
Pou3f2mutations die within 10 days of birth, whereas het-
erozygous mice have half-the-normal levels of vasopressin
and oxytocin in the hypothalamus in comparison with the
wild-type mice.27 This suggests that haploinsufficiency of
POU3F2 might affect hypothalamic development or func-
tions more specifically than other brain regions. The
hypothalamus is a critical integrator of neural and humor-
al signals that has, among its numerous functions, a funda-
mental role in controlling the body’s energy expenditure,
food intake, social behavior, learning, and memory.The AmericAbnormal development, survival, or function of hypotha-
lamic neurons is known to underpin a number of disorders
associated with obesity, hyperphagia, and abnormal neu-
rodevelopment.16 This further supports the putative role
of POU3F2 deletion in the phenotype seen in the individ-
uals described here. The similarity of the clinical features
described here with those caused by loss-of-function
SIM1 mutations11,12 is in keeping with our conclusions.
However, an interesting difference in individuals pre-
sented here is that hyperphagia was reported to develop
after the onset of obesity. The underlying reason or mech-
anism for this is not clear and will need identification of
younger pre-symptomatic individuals in the future to
confirm this observation.
The intellectual disability and neuropsychological prob-
lems associated with haploinsufficiency of POU3F2 and
SIM1might result fromdecreased oxytocin levels. Oxytocin
is required for activity-dependent cortical development and
cortical plasticity39 and is known to shape social learning40an Journal of Human Genetics 98, 363–372, February 4, 2016 369
and emotional responses. Future studies of disorders of
this pathway could help delineate the precise function of
oxytocin in human learning and behavior. Alternatively,
thephenotypemight also bedue to effects that are indepen-
dent from the role of oxytocin. For example, POU3F2 is
known to regulate FOXP2, mutations in which cause
speech-language disorder-1 (MIM: 602081).41,42
The phenotypic variability among individuals pre-
sented here is notable. For example, the phenotype
observed in individual 5 (family 2, individual II-1 in
Figure 1) is significantly milder than the clinical features
of individual 9 (family 5, individual II-1 in Figure 1).
The reason behind this is not clear. It could be due to
the differences in the size of their deletions—individual
5 has the smallest deletion that includes only two genes
(POU3F2 and FBXL4) and individual 9 has the largest dele-
tion that includes MCHR2 in addition to all the nine
genes deleted in family 1. Alternatively, genetic back-
ground or environmental factors might influence the
phenotype.
It is remarkable that SIM1 regulates POU3F2 and, in hu-
mans, both genes are located on 6q16.1, less than 1.6 Mb
apart. This raised the possibility that SIM1 and POU3F2
might share common regulatory regions, deletion of
which might have an effect on the 6q16 deletion
phenotype. To test this hypothesis, we examined the
evolutionary syntenic architecture of the region using
Genomicus browser,43 which showed that SIM1 and
POU3F2 are located on different chromosomes in a num-
ber of species, including mice (Figure S9). This reduces
the probability of shared regulatory regions between
SIM1 and POU3F2 on 6q16.1.
Notably, we have not described any individuals with
POU3F2 point mutations. Hence, a more complex mech-
anism, such as one involving long-range gene dysregula-
tion, cannot be completely ruled out to underlie the
phenotype seen with 6q16.1 deletions. It will be inter-
esting to see whether nonsense or loss-of-function
POU3F2 mutations can result in the same phenotype.
This question might be best answered by targeted
sequencing or interrogating exome sequencing data
from large cohorts of individuals with ID or obesity. We
interrogated data from more than 4,000 trios in the
DDD study44 and did not find any truncating POU3F2
mutation in this cohort. Intellectual disability and
obesity both are listed phenotypes in approximately 3%
of probands in the DDD study (C. Wright, personal
communication). Of note, POU3F2 is composed of a
single exon (Figure S10). Thus, truncating mutations
in this gene might not lead to nonsense-mediated
decay and, therefore, might not necessarily result in
haploinsufficiency. Second, the POU3F2 sequence is
extremely GC rich (Figure S10) and, therefore, accurate
sequencing might be challenging. Examination of
coverage metrics for POU3F2 in the ExAC database re-
vealed extremely poor coverage for almost 50% of the
gene (Figure S10).370 The American Journal of Human Genetics 98, 363–372, FebruaryIn summary, we have described overlapping 6q16.1 dele-
tions in ten individuals, from six families, with variable
developmental delay, intellectual disability, and suscepti-
bility to obesity and hyperphagia. The likely mechanism
is haploinsufficiency of POU3F2. Our work helps to further
define the neuro-endocrine control of energy balance/food
intake and its role in human monogenic obesity by
demonstrating that POU3F2 functions downstream to
SIM1 in the leptin > melanocortin > SIM1 > oxytocin
pathway and is an important mediator of the clinical and
biochemical effects (decreased oxytocin levels) of loss of
SIM1 activity. Our zebrafish work, previous work onmouse
models,17–19,27,28 the human phenotypes, and our analysis
of the expression patterning of these genes demonstrate
that the molecular pathway linking genes related to hypo-
thalamic function is conserved across species, emphasizing
its biological importance.Supplemental Data
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